The present invention is directed to bi-functional compounds which find use as pharmaceutical agents in the treatment of disease states and/or conditions which are through.macrophage migration inhibitory factor (MIF) or immunoglubin G (IgG). The present invention is also directed to pharmaceutical compositions which comprise these bi- functional compounds as well as methods for treating disease states and/or conditions which are mediated through MIF/lgG or where MIF/lgG is a contributing factor to the development and perpetuation of diseases and/or conditions, especially including autoimmune diseases and cancer, among others. The purpose of the present invention is to provide a molecular strategy to lower plasma MIF/lgG level in patients with autoimmune diseases or certain types of cancers. The b.i -functional molecule construct is comprised of a MIF/IgQ-targeting motif, that is derived from small molecule MIF/lgG ligands, and an ASGPr- targeting motif that binds to hepatocyte asialoglycoprotein receptor { ASGPr). The compounds selectively bind MIF or IgG in plasma and subsequently engage the endo-lysosomal pathway of hepatocytes through ASGPr. As a consequence, MIF/igG is internalized and degraded by hepatocytes, thus resulting in potential attenuation of corresponding disease symptoms which are modulated through MIF/igG.La présente invention concerne des composés bi-fonctionnels qui sont utiles en tant qu'agents pharmaceutiques dans le traitement d'états et/ou d'affections pathologiques qui sont médiés par un facteur inhibiteur de la migration des macrophages (MIF) ou une immunoglubine G (IgG). La présente invention concerne également des compositions pharmaceutiques qui comprennent ces composés bi-fonctionnels ainsi que des méthodes de traitement d'états et/ou d'affections pathologiques qui sont médiés par le MIF/IgG ou dans lesquelles MIF/lgG est un facteur contribuant au développement et à la perpétuation de maladies et/ou d'affections, notamment de maladies au
